Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	US$1.330	+2.31%	6,522
26-10-16	US$1.300	+1.56%	15,867
26-10-15	US$1.280	-5.19%	14,972
26-10-14	US$1.350	0.00%	23,163
26-10-13	US$1.350	+3.05%	18,050

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.330USD

Average target price

26.00USD

Spread / Average Target

+1,854.89%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzamend Neuro, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alzamend Neuro, Inc.

Company calendar

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
1.330 ^USD	+2.31%		+1.53%	-26.92%

09-10	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Market Cap	6.42M 5.72M 5.3M 4.82M 9.04M 609M 9.19M 63.57M 25M 318M 24.08M 23.58M 1.02B	P/E 2027 *	-1.27x	P/E 2028 *	-1.53x
Enterprise Value	6.42M 5.72M 5.3M 4.82M 9.04M 609M 9.19M 63.57M 25M 318M 24.08M 23.58M 1.02B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.34%	Yield 2027 *	-	Yield 2028 *	-

09-10	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
08-18	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
08-04	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-22	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
07-21	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
07-21	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
03-16	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
03-16	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
03-11	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
03-06	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

23-04-12	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
21-12-27	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
21-10-01	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Stock

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news: Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-20	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
08-18	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
07-22	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
04-07	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
03-26	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	+2.31%
1 week	+1.53%
Current month	-23.12%
1 month	-29.63%
3 months	+9.92%
6 months	+18.75%
Current year	-26.92%

1 week	1.25	1.4
1 month	1.2	1.95
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	280.8
5 years	0.84	4,562.86
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	2018-11-19
David Katzoff DFI	Director of Finance/CFO	64	2022-08-04
Henry Nisser LAW	General Counsel	57	2019-04-30

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	2016-02-25
William Horne CHM	Chairman	57	2021-05-31
Stephan Jackman BRD	Director/Board Member	50	2020-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
8/26/26	Todd Ault	Sell	Founder	-2,000	0.0417%
8/26/26	HYPERSCALE DATA, INC.	Other	Company	0	0%	-
7/31/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+2.31%	+1.53%	-40.09%	-99.52%	6.42M
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	65.83B
LONZA GROUP AG	+1.52%	+6.83%	+10.77%	+79.30%	51.87B
ARGENX SE	+0.30%	-0.46%	+2.53%	+61.89%	51.2B
IQVIA HOLDINGS INC.	-0.38%	+1.40%	+29.98%	+42.37%	43.76B
BEONE MEDICINES AG	+0.30%	+5.64%	+16.99%	+133.30%	42.09B
REVOLUTION MEDICINES, INC.	+2.35%	-6.08%	+236.69%	+528.10%	39.04B
CELLTRION, INC.	+2.16%	+9.87%	+18.92%	+59.70%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.40%	-2.63%	+38.77%	+8.24%	25.2B
GENMAB A/S	+1.60%	+2.21%	+21.34%	+28.00%	22.8B
Average	+1.52%	+0.40%	+38.75%	+91.14%	37.58B
Weighted average by Cap.	+1.28%	+0.20%	+46.47%	+114.01%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.63M -8.92M -8.11M -15.22M -1.02B -15.47M -107M -42.06M -535M -40.52M -39.67M -1.71B	-10.8M -9.63M -8.92M -8.11M -15.22M -1.02B -15.47M -107M -42.06M -535M -40.52M -39.67M -1.71B
Net Debt	-	-

Markets		Quality
Nasdaq	ALZN	Delayed
CBOE	ALZN	Real-time